Division of Cancer Treatment and Diagnosis- Operational Task Order

The Division of Cancer Treatment and Diagnosis (DCTD) supports the development of novel diagnostic and therapeutic approaches for cancer by expediting the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other diagnostic and therapeutic interventions in patients. Within DCTD, eight major programs and a patient clinic work together to bring unique molecules, diagnostic tests, and therapeutic interventions from the laboratory bench to the patient bedside. Activities supported under this contract include: isolation and evaluation of natural products; molecular pharmacology; high-throughput screening of compound libraries; pharmacodynamic marker and pharmacokinetic assay development and utilization in clinical trials; drug toxicology research; information systems, technologies, and data science; drug discovery; radiochemistry and radioactive drug production; archival of clinical trial images, in vitro and in vivo translational research; repository support for natural products, patient-derived xenografts, tumors and biologic anti-cancer agents; a biopharmaceutical production facility; medical writers; nursing support services for clinical trials performed in the NIH Clinical Center, correlative studies in collaboration with biopharmaceutical companies; support for precision medicine trials; advanced genomics capabilities supporting tumor evaluation in pre-clinical models and clinical trials; patient biorepositories for NCI-funded clinical trials; nanotechnology characterization and evaluation. Project Number: 75N91019D00024-0-759102500016-16 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: lynn briscoe | Institution: LEIDOS BIOMEDICAL RESEARCH, INC., FREDERICK, MD | Award Amount: $41,585,966 | Activity Code: N01 View on NIH RePORTER: https://reporter.nih.gov/project-details/11458397